TELA Bio, Inc. (NASDAQ:TELA – Get Free Report) CTO Paul Talmo purchased 22,222 shares of the company’s stock in a transaction that occurred on Thursday, October 24th. The shares were purchased at an average price of $2.25 per share, for a total transaction of $49,999.50. Following the purchase, the chief technology officer now directly owns 91,082 shares in the company, valued at $204,934.50. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
TELA Bio Stock Up 10.9 %
TELA opened at $2.86 on Friday. The company has a debt-to-equity ratio of 14.22, a current ratio of 3.41 and a quick ratio of 2.52. The business has a 50 day simple moving average of $2.66 and a 200-day simple moving average of $4.12. The stock has a market capitalization of $70.51 million, a P/E ratio of -1.71 and a beta of 0.99. TELA Bio, Inc. has a 12 month low of $2.30 and a 12 month high of $7.84.
TELA Bio (NASDAQ:TELA – Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.06). The business had revenue of $16.09 million during the quarter, compared to analyst estimates of $19.00 million. TELA Bio had a negative net margin of 65.04% and a negative return on equity of 252.57%. During the same period in the prior year, the business earned ($0.46) earnings per share. On average, equities analysts anticipate that TELA Bio, Inc. will post -1.39 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Stock Analysis on TELA
Institutional Trading of TELA Bio
Several hedge funds have recently modified their holdings of the business. Point72 DIFC Ltd acquired a new stake in shares of TELA Bio in the 2nd quarter valued at approximately $25,000. Vanguard Group Inc. raised its holdings in TELA Bio by 0.7% during the first quarter. Vanguard Group Inc. now owns 1,006,052 shares of the company’s stock worth $5,704,000 after purchasing an additional 7,199 shares during the last quarter. Embree Financial Group acquired a new position in TELA Bio during the third quarter worth $25,000. Ground Swell Capital LLC acquired a new position in TELA Bio during the second quarter worth $53,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in TELA Bio during the second quarter worth $115,000. 94.35% of the stock is owned by institutional investors and hedge funds.
TELA Bio Company Profile
TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
Recommended Stories
- Five stocks we like better than TELA Bio
- What Are Dividends? Buy the Best Dividend Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Compound Interest and Why It Matters When Investing
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.